| |
|
|
|
|
|
Bladder cancer is the most common tumor of the urinary system and the fifth most common cancer in North America. It is estimated that 75,000 new cases of bladder cancer will be diagnosed in 2008, and that 16,000 individuals will die from it. The World Health Organization estimates that there are 330,000 new cases annually worldwide. Bladder cancer prevalence is steadily increasing and its projected rise is 28 by 2010 for both men and women.
The diagnosis of bladder cancer currently relies on identifying malignant cells by urine cytology, with or without adjunct tests, and also by visualizing
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|
|
|
|
|
Noninvasive bladder volume instrument. Prevents unnecessary catheterization, reduces rates of urinary tract infection (UTI), assists in managing incontinence, and helps diagnose urinary and bladder dysfunction.
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|
|
|
|
|
The BladderScan® BVI 6100 is a handheld, noninvasive ultrasound instrument that measures bladder volume. It is easy to operate, so any staff member can scan patients quickly and accurately. To view ultrasound images from exams and print BVI 6100 exam results for patient records and reimbursement, just log on to ScanPoint®, the innovative online service from Verathon®. The BVI 6100 makes it easier to provide the best care for your patients.
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|
|
|
|
|
BladderScan® is the gold standard in bladder volume measurement. The BladderScan® BVI 9400, with patent-pending NeuralHarmonics™ technology, is a portable, noninvasive instrument that quickly and accurately measures urinary bladder volume and post-void residual (PVR) with 3D ultrasound.
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|
|
|
|
|
The BladderScan® BVM 6500 is the first "2 in 1" handheld ultrasound device for bladder diagnosis. It rapidly and noninvasively measures:
UEBW
Ultrasound-Estimated Bladder Weight
Bladder Volume
For post-void residual (PVR)
The UEBW application was designed to help Urologists diagnose bladder dysfunction, including bladder outlet obstruction (BOO). Some recent clinical studies indicate that bladder wall thickness and related bladder wall mass may correlate with bladder outlet obstruction (BOO). The BladderScan® BVM 6500 provides a noninvasive means of assessing bladder wall mass via portab
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|
|
|
|
|
The bladder tumor associated antigen has been shown to be produced by bladder tumor cells in cell culture and shed into the urine of bladder cancer patients where it can be detected using the BTA stat Test and/or BTA TRAK Assay. It has also been shown to be produced by bladder tumor cells using in situ hybridization. In addition, cultured cells, inlcuding bladder cancer cells, have been shown to be significantly more susceptible to lysis by complement in the presence of monoclonal antibodies specific for FH/CFHrp.
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|
|
|
|
|
FH is a soluble protein that protects normal cells from being destroyed by the complement system. Recent research has shown that many cancer cell lines, including bladder cancer, make variant FH molecules (CFHrp) presumably to protect themselves from being destroyed by the complement system. Production of this type of protein by the tumor may keep it from being destroyed even though the immune system recognizes it as foreign.
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|
|
|
|
|
The bladder tumor associated antigen detected by the BTA stat® Test and the BTA TRAK® Assay has been identified as complement factor H related protein (CFHrp), a variant of human complement factor H (FH). FH plays an important role in regulating the complement system.
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|
|
|
|
|
The Mobile BladderScan® instrument noninvasively performs and stores a minimum of ten patient bladder volume exams, each associated with a voice annotation, so healthcare providers can conveniently monitor patients’ bladder function on their rounds. The easy-to-use, handheld instrument provides an alternative to diagnostic urinary catheterization, eliminating unnecessary urethral trauma to the patient. Studies have shown that BladderScan® technology prevents unnecessary catheterization, reduces the incidence of catheter-related urinary tract infections, and improves satisfaction with care prov
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|
|
|
|
|
The NMP22® BladderChek® Test is the only in-office test approved by the FDA for the diagnosis of bladder cancer. The NMP22 BladderChek Test is a painless and non-invasive assay, performed on a single urine sample, that detects elevated levels of NMP22 protein.
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|